VEGFA and retinopathy of prematurity: Resistance to anti-VEGF therapy is sometimes observed in DR (including DME); therefore, developing a new therapy associated with low-grade inflammation as a “beyond VEGF” therapy for retinal vascular diseases, including DR and ROP, may be useful.